Accelerating Medical Treatments for Serious Mental Illness
Apr 22, 2026
Apr 22, 2026
Summary
Makes it easier to research and approve psychedelic drugs to help people with serious mental health problems, especially veterans.
What does this order do?
Prioritizes psychedelic drug review
Directs the FDA to give National Priority Vouchers to certain psychedelic drugs that have received a Breakthrough Therapy designation, speeding up their review process.
Creates a path for patient access
Requires the FDA and DEA to make it easier for eligible patients to access psychedelic drugs, including ibogaine, under the Right to Try Act.
Reference
Text:
Section:
Header:
Department of Health and Human Services Funding for Federal-State Collaboration.
Funds state-level research
Allocates at least $50 million from existing funds to support state governments that are creating programs to study psychedelic drugs for serious mental illnesses.
Reference
Text:
Section:
Header:
Department of Health and Human Services and FDA Collaboration with the Department of Veterans Affairs and the Private Sector.
Promotes data sharing between agencies
Orders the HHS, FDA, and VA to work together and with private companies to share data from clinical trials to help get new drugs approved faster.
Speeds up drug rescheduling
Requires the Attorney General to quickly review any Schedule I drug that has passed Phase 3 clinical trials to see if it can be moved to a different schedule.
Who does this affect?
- People with serious mental illnesses
- Veterans
- Medical researchers and pharmaceutical companies
What is the real world impact?
•
Provides new hope for veterans and others with severe mental illness
Aims to find better treatments for people, particularly veterans, who are not helped by current medicines by exploring promising psychedelic drugs.
•
Encourages private investment in psychedelic drug development
Creates a clearer path for FDA approval and provides funding, which may encourage more private companies to invest in researching and developing these new therapies.
•
Raises concerns about fast-tracking controversial drugs
Some may worry that speeding up the approval of Schedule I substances like psychedelic drugs could overlook potential risks or lead to misuse before they are fully understood.
What problem does this solve?
Many Americans, especially veterans, suffer from serious mental illnesses, and current treatments do not always work. This order speeds up the study and approval of psychedelic drugs, which show promise as new treatments for these conditions.
When does this start?
This order takes effect on April 18, 2026, and directs federal agencies to begin taking action immediately.